Home › Thyroid Cancer › NCT04589624
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Be willing and able to provide informed consent * Be informed of the investigational nature of this study * Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment Exclusion Criteria: * Have a history of severe claustrophobia * Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI) * Have a history of cardiac arrhythmia * Have an allergy to Gadavist intravenous contrast * Estimated glomerular filtration rate (eGFR) \< 30 * If female, be pregnant or breast feeding at time of consent
About the study
This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.
What is being tested
- Hyperpolarized Carbon C 13 Pyruvate (drug)
- Magnetic Resonance Imaging (procedure)
- Magnetic Resonance Imaging (procedure)
Sponsor: M.D. Anderson Cancer Center · Participants: 42 · Started: Aug 12, 2020
Contact the study team
- Stephen Y Lai · Phone: 713-792-6528
Official record on ClinicalTrials.gov — NCT04589624
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.